BIO-Europe Spring 2017 backs Barcelona as the future HQ of the European Medicines Agency
On the occasion of the BIO-Europe Spring 2017 event in Barcelona, the newspaper “La Vanguardia” has published an article about the campaign to host the new headquarters of the London-based European Medicines Agency (EMA) after Brexit.
The article also includes a reference to the participation of IRB Barcelona’s Innovation Department in this three-day partnering conference for the biotechnology industry.
Related content
News
Iproteos, one of the 5 spin-offs launched by IRB Barcelona, focuses on the development of third-generation drugs for diseases such as schizophrenia, epilepsy, and atherosclerosis.
Its proprietary technology allows faster research processes to identify new drugs and produce novel molecules.
The new company Accure Therapeutics starts up with €7.6 M of investment, which will allow the development of its product portfolio and the takeover of Iproteos and Bionure.
Several media have reported on the collaboration of Nostrum Biodiscovery, a company cofounded by IRB Barcelona researcher Modesto Orozco, with Grifols and IrsiCaixa. This spin-off company from IRB Barcelona will contribute to research into COVID-19 by providing data that will facilitate the intelligent design of drugs in silico for the treatment of coronavirus.
Various media have reported on studies addressing COVID-19 to be undertaken by several research centres in Catalonia. Among the groups involved is IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy. IRB Barcelona is one of eight research centres chosen by the European Commission to study new approaches to treat and diagnose COVID-19 and thus halt the spread of the virus.
